Hongchang International Co., Ltd

HCIL

US42831T2024

Pharmaceuticals

Delayed OTC Markets Other stock markets 09:30:45 2024-03-08 am EST			5-day change	1st Jan Change
0.2226 ^USD	-.--%		-.--%	-36.18%

Apr. 01	Hongchang International Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Apr. 01	Hongchang International Co., Ltd Announces Board Changes	CI

Heyu Biological Technology Corporation Auditor Raises 'Going Concern' Doubt

March 22, 2023

Heyu Biological Technology Corporation filed its 10-K on Mar 23, 2023 for the period ending Dec 31, 2022. In this report its auditor, WWC, P.C., gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Latest news about Hongchang International Co., Ltd

Hongchang International Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Hongchang International Co., Ltd Announces Board Changes	Apr. 01	CI
Hongchang International Co., Ltd. has Changed its Ticker to HCIL from HYBT	Nov. 28	CI
Heyu Biological Technology Corporation has Changed its Name to Hongchang International Co., Ltd	Nov. 21	CI
Hongchang International Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Hong Chang Biotechnologies (HK) Limited completed the acquisition of Heyu Biological Technology Corporation (OTCPK:HYBT.D) in a reverse merger transaction.	23-09-03	CI
Heyu Biological Technology Corporation Appoints Zengqiang Lin as the Chief Executive Officer	23-08-23	CI
Heyu Biological Technology Corporation Announces Board and Executive Changes	23-08-23	CI
Heyu Biological Technology Corporation Appoints Wendy Wei Li as the Chief Financial Officer of the Company	23-08-23	CI
Hong Chang Biotechnologies (HK) Limited entered into an agreement to acquire Heyu Biological Technology Corporation (OTCPK:HYBT.D) in a reverse merger transaction for HKD 4.4 billion.	23-08-22	CI
Heyu Biological Technology Corporation Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-16	CI
Insider Buy: Heyu Biological Technology	23-05-31	MT
Heyu Biological Technology Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Heyu Biological Technology Corporation Auditor Raises 'Going Concern' Doubt	23-03-22	CI
Heyu Biological Technology Corporation Appoints Zengqiang Lin as an Independent Director of the Company	23-02-22	CI
Heyu Biological Technology Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	23-02-13	CI
Heyu Biological Technology Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	23-02-10	CI
Heyu Biological Technology Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-24	CI
Heyu Biological Technology Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-15	CI
Heyu Biological Technology Corporation Auditor Raises 'Going Concern' Doubt	22-04-14	CI
Heyu Biological Technology Corporation Auditor Raises 'Going Concern' Doubt	22-03-31	CI
Heyu Biological Technology Corporation Appoints Bo Lyu as Chief Financial Officer	21-11-30	CI
Heyu Biological Technology Corporation Announces CFO Changes	21-03-04	CI
Heyu Biological Technology Corporation Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-16	CI
Heyu Biological Technology Corporation Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-14	CI

Chart Hongchang International Co., Ltd

Duration

Period

More charts

Company Profile

Hongchang International Co Ltd, formerly Heyu Biological Technology Corp, is a holding company mainly engaged in research and development and manufacture a medical product, the Submillimeter Wave (Terahertz) Quantized Space Therapy Chamber (the Chamber). Utilizing submillimeter waves, the Chamber is a medical equipment designed to treat cancer through cold nuclear fusion caused by cosmic ray muons in an enclosed chamber.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HONGCHANG INTERNATIONAL CO., LTD	-36.18%	115M
ELI LILLY AND COMPANY	+25.99%	661B
NOVO NORDISK A/S	+26.74%	566B
JOHNSON & JOHNSON	-6.64%	352B
MERCK & CO., INC.	+18.78%	332B
ABBVIE INC.	+3.45%	283B
ASTRAZENECA PLC	+13.43%	231B
NOVARTIS AG	+4.71%	200B
ROCHE HOLDING AG	-9.53%	195B
AMGEN INC.	-4.32%	145B